2 hours Outlook Therapeutics’ (OTLK) Buy Rating Reiterated at BTIG ResearchMarketBeat
BTIG Research reiterated a “buy” rating and set a $50.00 target price on shares of Outlook Therapeutics in a research report on Friday.
XBTIG Research reiterated a “buy” rating and set a $50.00 target price on shares of Outlook Therapeutics in a research report on Friday.
X